News

The European Commission’s approval allows Jerini to market Firazyr in the EU’s 27 member states, making it the first product to be approved in all EU countries for

EpiCept will receive approximately $0.5 million in net proceeds from the offering. Rodman & Renshaw, a subsidiary of Rodman & Renshaw Capital Group, is acting as the exclusive

In connection with the private placement, investors received three year warrants to purchase an aggregate of 4.3 million shares of common stock at an exercise price of $0.90

The Phase Ia trial is a placebo-controlled single ascending dose clinical trial. The trial is designed to evaluate the safety and tolerability of A0001 at various doses and

Additionally, based on current discussions, Hemispherx management sees the potential for a mutually beneficial new Ampligen partnership with the principals now controlling Bioclones and Ribotech. As part of

WellPoint is currently partnering with CareNex to expand its affiliated health plans’s Neonatal Intensive Care (NICU) services program for members in those plans in Virginia and New York,

As previously announced, Allergan paid approximately $150 million for all assets relating to Aczone gel 5%. Allergan expects to launch Aczone gel 5% in the fourth quarter of

Under the terms of the agreement, rights to ViroNovative’s human metapneumovirus (hMPV) intellectual property will be extended to Luminex’s distributors and end-user customers around the world. Luminex’s xTAG

The safety data from the final analysis also shows that vernakalant (oral) was well-tolerated in the atrial fibrillation population studied. The final results demonstrated that the 500mg dosing